












660The Evolving Role of Stem Cell Transplants
in Lymphomas
Esa Jantunen,1 Anna Sureda2Autologous stem cell transplantation (ASCT) is an established therapeutic modality in the treatment of lym-
phomas, especially in the relapse setting. It is also under investigation after first-line therapy, for example, in
patients with mantle cell or T cell lymphomas. Each year more than 6000 autotransplants for lymphomas are
reported to the European Blood and Marrow Transplantation (EBMT) registry. The number of allogeneic
stem cell transplantations (alloSCT) in lymphoma patients has increased over the last decade, with about
1200 transplanted lymphoma patients annually reported to the registry. Optimal timing and indications
for alloSCT are not well defined because of absence of randomized trials. Developments in the treatment
of lymphomas including immunotherapy have changed the clinical scenarios in regard to ASCT, andmany pub-
lished studies are now outdated. On the other hand, patients relapsing after immunochemotherapy may
derive less benefit from ASCT. Consequently, there is an increasing interest in using alloSCT not only in lym-
phoma patients relapsing after ASCT but also in earlier phases in specific circumstances. Although curative
potential is higher with alloSCT compared with ASCT, its wider use has been hindered by excessive non-
relapse mortality (NRM). Along with decreasing NRM figures, popularity of alloSCT may increase in the
near future, possibly with the expense of ASCT. Prospective, randomized studies are needed to evaluate
feasibility and efficacy of alloSCT in several clinical settings, as most published evidence is based on retrospec-
tive registry data or single-center experiences.
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According to the recent activity survey by the
European Group for Blood and Marrow Transplanta-
tion (EBMT) [1], about 8000 stem cell transplanta-
tions were reported in lymphoma patients in 2008.
There were altogether 6734 autologous stem cell
transplantations (ASCT) (non-Hodgkin lymphoma
[NHL] 4815, Hodgkin’s lymphoma [HL] 1919) and
1172 allogeneic stem cell transplantations (alloSCT)
(NHL 887, HL 285). Although there is only a slight
increase in the number of ASCTs performed in lym-
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6/j.bbmt.2011.09.009alloSCTs is continuously rising and has about doubled
from 2001 to 2010 (EMBT Lymphoma Working
Party, unpublished) (Figure 1). The majority of
alloSCTs are currently performed with mobilized
blood stem cells. The number of transplantations
from unrelated donors has increased recently as well
as the number of transplantations using reduced-
intensity conditioning (RIC) (Figure 2).
Recent developments in the field of both conven-
tional treatment of many lymphomas as well as devel-
opments in transplant practices have resulted in the
continuously evolving role of stem cell transplant
approaches in this patient group. Improvements in
lymphoma therapy challenge the current role of
ASCT at least in some subtypes. Most of the random-
ized studies evaluating the role of ASCT performed
within the last 2 decades are outdated as they have
not included immunotherapy. For example, the addi-
tion of rituximab to CHOP therapy has improved out-
comes of both younger [2] and elderly patients [3] with
diffuse large B cell lymphoma (DLBCL). Similarly,
addition of rituximab to the first-line therapy [4] or at
relapse [5] has improved the prognosis in patients
with follicular lymphoma (FL). Also, dose-intensified
chemotherapies in patients with DLBCLmay improve
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Figure 1. The number of allogeneic stem cell transplantations in
lymphoma patients reported to the EBMTregistry 2001-2010.
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Figure 2. The number of allogeneic stem cell transplantations accord-
ing to the type of conditioning in lymphoma patients reported to the
EBMT registry 2001-2010. MAC indicates myeloablative conditioning;
RIC, reduced-intensity conditioning.
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patients with mantle cell lymphoma (MCL) have
been reported using rituximab plus intensive alternat-
ing chemotherapy without ASCT [8]. Despite im-
provements in lymphoma therapy, a significant
proportion of lymphoma patients still fail to achieve re-
mission or relapse and ultimately die because of pro-
gressive lymphoma.
Traditionally, high nonrelapse mortality (NRM)
has been the major drawback of alloSCT and has
been the major obstacle for its wider use in lymphoma
patients. With better patient selection in the earlier
course of the disease and notably with the advent of
less toxic conditioning regimens (ie, RIC), the mortal-
ity rates because of nonrelapse reasons are continu-
ously decreasing. Consequently, NRM figures of
15% to 30% at 2 or 3 years have been reported in
more recent series making this treatment option
more appealing. Furthermore, there is evidence that
in analogy to graft-versus-leukemia effect, also graft-
versus-lymphoma (GVL) effect exists, which is shown,
for example, in lower risk of relapse after alloSCT
when compared with ASCT and also clinical efficacy
of donor lymphocyte infusions (DLI) for treatment
of relapse after alloSCT. Importance of GVL is also
supported by the clinical responses observed in re-
lapsed patients following withdrawal of immunosup-
pression and also by the lower relapse risk in patients
with chronic graft-versus-host disease (cGVHD).
The lower risk of relapse after alloSCT may also in
part be because of tumor-free graft.
Continuously improving results of modern non-
transplant therapies challenge the role of ASCT in
many clinical settings. There are still patient groups
where we should clearly improve. These include
patients with DLBCL who relapse after immunoche-
moherapy, FL patients relapsing after immunochemo-
therapy (6 rituximab maintenance), patients with
poor-risk MCL, patients with systemic peripheralT cell lymphoma (PTCL), and those with poor-risk
HL (refractory or early recurrence). In these clinical
scenarios, innovative therapies are needed in order to
improve outcome. Despite higher risks, alloSCT may
in some circumstances offer a viable alternative in
some patients who relapse after ASCT or even substi-
tute ASCT. This review attempts to discuss the role of
ASCT and alloSCT in themajor histologic subtypes of
NHL andHL.We also refer here to the recent EBMT
paper on transplant practices in Europe [9].
DLBCL
DLBCL is the most common NHL subtype and
also the most common indication of ASCT among
lymphomas. Advances in therapy notably rituximab
have improved outcome of patients with DLBCL.
For the same reason, numerous randomized studies
evaluating ASCT performed mostly in 1990s are out-
dated and need repetition [10]. Treatment of relapsed
DLBCL in the era of modern immunotherapy is more
challenging as evolved first-line therapy may select
more aggressive and less chemosensitive tumor cell
clones at relapse.
Autologous transplantation
At least 15 randomized studies including more
than 3000 patients comparing chemotherapy with
chemotherapy followed by ASCT after the first-line
therapy have been performed. Inclusion criteria as
well as protocols have varied. In a recent meta-
analysis, no difference in outcome between the stan-
dard arm and the ASCT arm could be observed [11].
Several randomized studies comparing immunoche-
motherapy with or without ASCT in patients at high
risk based on the International Prognostic Index (IPI)
are currently ongoing. A recent study by GOELAMS
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I-II with bulk did not observe any difference in survival
between the patients receiving 8 R-CHOP-14 or ran-
domized to the high-dose arm (R-high-dose CHOP
 2, high-dose methotrexate, high-dose cytarabine
and BEAM 1 ASCT). Likewise, the German Mega-
CHOEP trial failed to show advantage over conven-
tional dose therapy (CHOEP-14 8) in the rituximab
era among 306 patients with age-adjusted IPI 2 or 3
[13]. An Italian study including 414 patients with
age-adjusted IPI 2-3 randomized to receive
R-CHOP-14  8, intensified CHOP-14  6 (cyclo-
phosphamide 1200 mg/m2, doxorubicin 70 mg/m2),
R-CHOP-14  4 1 ASCT, or intensified CHOP-14
 4 plus ASCT has just been reported. Although the
relapse risk was reduced in ASCT arm (progression-
free survival [PFS] at 2 years 72% versus 59%,
P 5 .008) when compared with nontransplant arms,
no difference in overall survival (OS) was seen [14]. It
is possible that biologic prognostic factors may reveal
patient groups who may benefit from up-front ASCT
[15], but this issue should be evaluated in the immuno-
therapy era.
Primary refractory patients who respond to salvage
chemotherapy should proceed to ASCT. According to
a single-center study 22% of these patients were event-
free (EFS), and OS was 44% at 3 years in patients who
proceeded to ASCT [16]. On the other hand, ASCT is
not an option in chemorefractory patients [9].
Based on the classical Parma study [17], ASCT is
considered the standard of care in patients with che-
mosensitive relapse. In this randomized study,
DHAP, followed by BEAC 1 ASCT, was superior to
DHAP alone with 5-year EFS of 46% versus 12% (P
5 .001) and OS of 53% versus 32% (P5 .038), respec-
tively. Unfortunately, there are no randomized pro-
spective studies in this patient group in the rituximab
era. There are data suggesting that patients who re-
lapse after immunochemotherapy may have poorer
outcome even with ASCT than patients relapsing after
chemotherapy. In the retrospective Spanish study [18],
PFS was inferior (17% versus 57% at 3 years, P \
.0001), as well as OS (38% versus 67% at 3 years, P
5 .0005) in patients who had received rituximab dur-
ing the first-line therapy and were intended to receive
ASCT after ESHAP salvage chemotherapy. Also, the
recently published CORAL trial [19] showed that the
outcome of patients refractory to or relapsing after im-
munochemotherapy is poor after R-ICE or R-DHAP
followed by ASCT. Although the response rate (com-
plete response [CR] or partial response [PR]) in both
treatment arms was about 63% and these patients
were eligible for ASCT, EFS was only 21% at 3 years
in patients who had received immunochemotherapy in
the first-line compared with 47% (P\ .001) in patients
who did not receive rituximab as a part of induction
therapy. Other factors affecting 3-year EFS in thisstudy included IPI 2-3 versus 0-1 (18% versus 40%,
P\ .001) and relapse\12 months (20% versus 45%,
P \ .0001). Addition of ibritumomab tiuxetan to
BEAM regimen may improve outcome in low-risk pa-
tients (remission .12 months and IPI score at relapse
\3)] in a small prospective randomized study includ-
ing 43 patients a PFS of 61% at 2 years was observed
in those patients [20]. Patients relapsing soon (\12
months) after immunochemotherapy have such poor
outcome with ASCT, that alloSCT might be consid-
ered in patients with chemosensitive disease instead.
Prospective clinical trials looking at the potential
role of alloSCT in this situation are urgently needed.
Allogeneic transplantation
Historically, patients with relapsed DLBCL have
not often been considered for alloSCT because of
the anticipated high risk of NRM. This scenario is,
however, gradually changing. This is, in part, because
of the relatively poor outcome of ASCT in patients
who relapse early (\12 month) after immunochemo-
therapy and in part to the fact that NRM seems to be
decreasing in more recent patient series. In 2000 to
2008, about 18% of all alloSCTs were performed in
patients with DLBCL according to the registry of
the EBMT Lymphoma Working Party.
There are indications that the GVL effect may be
operating at least in some patients with DLBCL as
immunosuppression withdrawal with or without DLI
has resulted in clinical responses [21]. In a Seattle series
including 30 patients with relapsed DLBCL and using
very low-intensity conditioning (total body irridation
[TBI] 2 Gy1 fludarabine 27 patients, TBI 2 Gy alone
in 3 patients), NRM and PFS were 25% and 45% at
3 years, respectively [22]. Seventy-five percent of these
patients had received a prior ASCT, and disease status
at the time of allo SCT included CR in 44%, PR in
28%, and refractory 28%, respectively. In the French
registry analysis of RIC transplants in 68 patients
(fludarabine-based in all except 1 patient plus other
chemotherapy in 74% of the patients and TBI in
25% of the patients; HLA-identical sibling donor in
82% of the patients), NRM at 1 year was 23% [23].
PFS and OS at 2 years were 44% and 49%,
respectively. In the United Kingdom series including
48 patients (30DLBCL, 18 transformed FL; a previous
ASCT in 71% of the patients) who received condition-
ing with alemtuzumab, fludarabine, and melphalan
(140 mg/m2) and the donor was an HLA-identical
sibling in 62% of the patients, NRM at 4 years was
32% and PFS and OS were 47% and 48% at 4 years,
respectively [24]. A recent study by the EBMT
Lymphoma Working Party [25] showed an NRM of
28% and OS of 54% at 3 years among 101 patients
who had relapsed after ASCT. NRM was higher in
patients older than 45 years (P5 .02), those with early
relapse (\12 months from ASCT) (P 5 .01), and in
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with longer remission after ASCT and sensitive disease
appeared to be the best candidates for alloSCT. In this
study, 37 patients received myeloablative conditioning
and the donor was an HLA-identical sibling in 72 pa-
tients. Matched unrelated donors may be comparable
to sibling donors according to theEBMTregistry anal-
yses [25,26].
Taken together, even based on relatively small and
heterogeneous retrospective series, it appears that
alloSCT is an option in patients who relapse after
ASCT and in some patients with poor-risk first relapse
(relapse\12 months, high IPI). Although GVL may
be operating, biologic features of the lymphoma im-
plies that chemosensitivity and low tumor burden at
transplantation are important for long-term success.
These patients may also need more intensive condi-
tioning regimens. Only a minority, perhaps 20% to
40% of transplant-eligible patients with relapsed
DLBCL, can proceed to alloSCT as the disease is of-
ten not very sensitive to salvage therapy at this point
or the response is of too short duration to allow all
the logistics associated with alloSCT, at least in the
unrelated setting. There is a need to prospectively
compare ASCTwith alloSCT in patients with relapsed
DLBCL with poor-risk features. This may give some
estimates whether it is possible to identify a subgroup
of patients whomight eventually benefit from alloSCT
as their first transplant.
Follicular Lymphoma
The addition of rituximab to the first-line therapy
in patients with FL [4] or to the second-line therapy
[5] has considerably improved the outcome of these pa-
tients. More recently, rituximab maintenance has been
shown to improve survival in patients with high tumor
burdens achieving CR or PR with immunochemother-
apy in the randomized PRIMA trial [27]. At present,
however, there is no clear evidence suggesting that ad-
vanced-stage FL can be cured with immunochemo-
therapy. Furthermore, a significant proportion of
patients will show transformation to DLBCL with
poor outcomes [28]. Also, long-term effects of repeated
cycles of chemotherapy may become a more important
issue in accord with prolonged survival of the patients.
It is unclear whether patients relapsing after immuno-
chemotherapy, especially those receiving long-term
rituximab maintenance, will respond to subsequent
lines of therapy such as rituximab-naive patients.
Autologous transplantation
Several randomized studies have evaluated the role
of ASCT in FL patients after first-line chemotherapy
[29-31]. Two studies found better PFS [29] or EFS
[30] in the ASCT arm but failed to show any improve-
ment in OS. Of note, prolonged follow-up of the
patients treated in the GOELAMS study [32] observeda plateau in the PFS curve after 7 years, suggesting that
a minority of patients may be cured using an upfront
ASCT. All these studies were performed before ritux-
imab era. In an Italian study including rituximab,
Ladetto and coworkers [33] observed better PFS in
patients receiving high-dose sequential therapy when
compared with R-CHOP but without improvement
in OS. Consequently, ASCT is not recommended as
a part of first-line therapy unless the patient can be
included in a prospective clinical trial.
The randomized CUP study showed that ASCT
gives better EFS and OS than conventional chemo-
therapy in patients with relapsed FL [34]. In this study,
including 140 registered patients, of which 89 were
randomized after 3 cycles of chemotherapy to either re-
ceive 3more chemotherapy cycles or ASCTwith either
unpurged or purged marrow grafts, PFS was better in
the transplant arms (P 5 .037) and OS was better
(P 5 .079), with a median follow-up of 69 months.
Several phase II studies are also in line with this obser-
vation [35,36]. All these studies have been made before
the rituximab era. However, if a patient experiences
a relapse shortly (eg, \2 years) after immuno-
chemotherapy, some form of transplant approach
may be considered in younger patients. There are no
randomized studies comparing ASCT with second-
line chemotherapy followed by rituximab maintenance
or radioimmunotherapy in patients with relapsed FL.
If a relapse is observed shortly after rituximab mainte-
nance or during maintenance, transplant approach
should be considered in younger patients. In terms of
safety issues, ASCT is preferable. Rituximab mainte-
nance after ASCTprolongs PFS in rituximab-naive pa-
tients but without improvement in OS [37]. A recent
French study suggests that ASCT after the first relapse
is associated with favorable outcome (EFS 52% at 3
years) also in patients previously exposed to rituximab
[38]. Addition of radioimmunotherapy to BEAM regi-
men (Z-BEAM) has shown promising preliminary re-
sults in a phase II study of GELA with EFS and OS
of 63% and 97% at 2 years, respectively [39].
If FL transforms to DLBCL but is still chemosen-
sitive, ASCT is an effective approach based on phase II
and registry data. Hamadani and coworkers [40] ob-
served an OS of 52% at 3 years among 24 patients
with transformed FL who received ASCT (62%
treated with rituximab). In the EBMT registry series
including 50 patients with a transformed FL (no ritux-
imab), OS and PFS at 5 years were 51% and 30%,
respectively [41].
Allogeneic transplantation
GVL effect is important in FL as shown in the reg-
istry study comparing outcomes after ASCT and
alloSCT [42], although other factors such as tumor-
free graft may have a role. In that analysis, relapse
rate was substantially lower in allotransplanted
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alloSCT patients (30% versus 14% in patients with
a purged autograft and 8% in those with an unpurged
graft). In some recent studies, lower risk of NRM after
alloSCT has been reported. In the retrospective study
from the United Kingdom using a conditioning con-
sisting of alemtuzumab, fludarabine, and melphalan
and 74% of the patients having an HLA-identical
donor, NRM was only 11% in patients with low-
grade lymphomas (mostly FL), and PFS and OS at 3
years were 65% and 73%, respectively [43]. In the se-
ries from the M.D. Anderson Cancer Center [44] in-
cluding 47 patients with relapsed FL who received
a conditioning consisting of fludarabine, low-dose cy-
clophosphamide, and rituximab and all but 2 patients
received grafts from an HLA-identical sibling donor,
OS and PFS were 85% and 83%, respectively (median
follow-up 60 months).
T cell–depleted RIC allografting may be associ-
ated with a favorable outcome. Among 82 patients
treated at UK centers, NRM was only 15% at 4 years
and PFSwas as high as 76% [45]. On the other hand, in
the retrospective registry study of the EBMT, alemtu-
zumab, or antithymocyte globulin treatment reduced
the risk of GVHD but had no impact on NRM, which
was 17% at 3 years in the whole patient group [46]. In
this study, T cell–depleted transplants were associated
with higher risk of relapse and a trend for shorter PFS.
DLIs have been shown to be effective in FL patients
relapsing after alloSCT [43,45].
In the EBMT survey including 131 patients with
matched unrelated transplants, NRM was 30% at
1 year, and OS and PFS were 51% and 47% at 3 years,
respectively [47]. Radioimmunotherapy with ibritu-
momab tiuxetan has been shown to be feasible with
anRIC regimen [48,49], but further studies are needed.
Compared with ASCT, RIC alloSCT was associ-
ated with higher NRM (15% versus 3%) but better
PFS (57% versus 48% at 2 years) in the recent
EBMT registry series [50]. However, there was no dif-
ference in OS between these transplant approaches.
The best timing of alloSCT in FL is unclear.
AlloSCT can be considered in patients who relapse
after ASCT. Also, some younger patients with high-
risk relapse (early, advanced stage) after immunoche-
motherapy might be considered, especially it they
have low risk scores for NRM [51]. However, there
are no prospective clinical trials demonstrating a po-
tential advantage of alloSCT in this clinical setting.
Considering the quite strong GVL effect in this lym-
phoma type, RIC is recommended if there are no signs
of histologic transformation.
MCL
Conventional therapy for MCL has improved sub-
stantially with the addition of rituximab to chemother-
apy [52] and high-dose cytarabine in protocols [8], butin general, the disease is still considered incurable with
conventional chemotherapy [53].
Autologous transplantation
The majority of the experiences regarding ASCT
in patients with MCL are based on phase II studies
[54-58] or a retrospective registry series [59]. There
is only one randomized phase III trial that included
CHOP-like initial therapy followed by randomization
to ASCT or interferon maintenance among 122 pa-
tients with MCL [60]. In this study, PFS was signifi-
cantly longer in the ASCT arm (39 months versus
17 months, P5 .01), but OS at 3 years was comparable
(83% versus 77%). This study as well as themajority of
phase II studies did not include rituximab.
The largest phase II study (MCL-2) during the rit-
uximab era was performed by the Nordic Lymphoma
Group (NLg) [58] and used augmented CHOP alter-
nating with high-dose cytarabine and combined with
rituximab followed by ASCT (BEAM) in patients
#65 years of age. In this study, anOS of 70% at 6 years
was observed. More important, PFS was 66% at 6
years. This result is superior to earlier (Nordic Lym-
phoma Group) NLG experience using intensified
CHOP induction, which resulted in a lower probabil-
ity of CR and less impressive survival. Mantle cell In-
ternational Prognostic Index was superior to IPI in
predicting survival in the NLG-MCL2 study [61].
Preemptive therapy with rituximab based on the detec-
tion of molecular relapse post-ASCT was feasible and
seemed to prevent clinical relapses after ASCT [62].
The recent trial of the EuropeanMantle Cell Lym-
phomaNetwork compared 6 courses of R-CHOPwith
3 courses of R-CHOP and R-DHAP followed by
ASCT, and concluded that both remission rate and
outcomes were superior in the latter arm, which also
included high-dose AraC in the conditioning regimen
[63]; TBI was included in the both arms. The role of
TBI in the conditioning regimen in patients with
MCL having ASCT is a matter of debate. A recent ret-
rospective EBMT registry series suggests a superiority
of TBI-based conditioning in patients who were in first
partial remission at the time of transplantation [64]. On
the other hand, a single-center series suggests no differ-
ence betweenBEAMandTBI-based conditioning [65].
As molecular remission appears to be an indepen-
dent predictor for clinical outcome [66], all efforts
that increase the proportion of patients achieving this
goal are likely to be associated with improved long-
term outcome. There are several potential ways to
improve by including new drugs to induction therapy,
addition of radioimmunotherapy to high-dose chemo-
therapy (eg, Z-BEAM), or maintenance therapy with
antibodies after ASCT. Another large phase II study
has been recently completed by the NLG. In that
study, which was based on the previous phase II study
[58], the patients who were not in complete remission
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momab tiuxetan followed by BEAM (Z-BEAM) [67].
Although some controversies about the relative
merits of consolidation of the first-line response by
ASCT when compared with a nontransplantation ap-
proach continues to exist [8,68], intensive induction
therapy including an antibody followed by ASCT
might be considered as standard of care in MCL
patients up to 65 to 70 years of age, provided that they
are otherwise fit. Early NRM is also acceptable (3%-
4%) in elderly patients receivingASCT[69]. A random-
ized phase III study including rituximab is needed in
order to show potential superiority of the first-line
ASCT in MCL.
Allogeneic transplantation
Limited experiences with alloSCT in this subtype
are based on single-center series or registry analyses.
GVL effect seems to be present also in MCL [70,71].
In the study from theM.D. Anderson Cancer Cen-
ter [72] in 35 relapsed or refractory patients using RIC
(fludabine 1 TBI 2 Gy), 17 patients had an unrelated
donor and 14 had failed a prior ASCT. In this study,
NRM was 24% at 2 years. The disease-free survival
and OS were 56% and 60% at 2 years, respectively.
In the recent series from the United Kingdom [73],
70 patients with MCL received RIC-alloSCT, 57 of
them with an alemtuzumab containing regimen.
Thirty-four percent of the patients had relapsed after
ASCT. NRM was 18% and 21% at 1 year and 5 years,
respectively. OS at 5 years was 35%, but PFS was only
14%. Younger age,\2 prior lines of therapy, and use
of alemtuzumab in conditioning were associated with
better OS in this series.
The largest series of allotransplanted MCL
patients have been analyzed by the EBMTLymphoma
Working Party [74]. The analysis included 325 pa-
tients with RIC alloSCT; one-half of the patients
had undergone a previous ASCT. An NRM of 12%
and 34% at 100 days and 3 years were reported, respec-
tively. PFS was 49% at 1 year and 32% at 3 years,
respectively. The outcomes were negatively affected
by refractory disease and the use of an unrelated donor.
Although limited published data is available,
alloSCT can be considered a clinical option in patients
who relapse after ASCT and in selected patients who
relapse after nontransplantation first-line therapy.
PTCLs
PTCLs comprise a heterogeneous group of NHLs
representing \10% of all NHLs in the Western
world. Because of the absence of randomized clinical
trials, there is no gold standard for first-line therapy
in patients with systemic PTCLs. The outcome of pa-
tients of many subtypes is considered to be poor, with
the exception of alk-positive anaplastic large cell lym-
phoma (ALCL). In the recent report by the Germanhigh-grade non-Hodgkin Lymphoma Study Group
of patients treated withCHOEP/CHOP,OS at 3 years
ranged from 54% (PTCL-not otherwise specified) to
as high as about 90% in alk-positive ALCL [75].
Especially poor prognosis has been observed in rare
enteropathy-associated T cell lymphoma (EATL)
with a cure rate of only 10% to 20% [76,77].
Considering the generally poor outcome of
patients with systemic PTCLs, several studies have
evaluated the role of ASCT andmore recently alloSCT
either to consolidate response after first-line treatment
of relapse [78].
Autologous transplantation
Only few prospective phase II studies have been re-
ported regarding the first-line use of ASCT in patients
with PTCLs. The Italian study including 62 patients,
of which 46 underwent ASCT, resulted in estimated
12-year OS and EFS of 34% and 30%, respectively
[79]. The German study [80] evaluated 4 to 6 courses
of CHOP, followed by mobilizing chemotherapy,
TBI-cyclophosphamide conditioning and ASCT in
83 patients with PTCL. Fifty-five patients (66%) actu-
ally received ASCT. OS and PFS at 3 years were 48%
and 36%, respectively. The largest phase II study was
performed by the NLG and included 160 patients with
PTCL [81]. The treatment consisted of CHOEP-14
for 6 cycles followed by ASCT. Seventy percent of
the initially included patients went on to ASCT. OS
and PFS at 3 years were 57% and PFS 48%, respec-
tively. NRM was 4% in this study.
Outcome of first-line ASCT including treatment
strategy may depend on subtype. In patients with
alk-negative ALCL, the NLG trial observed an excel-
lent outcome with OS and PFS of 73% and 64% with
a median follow-up of 45 months, respectively [82].
This seems to be better than the recently reported re-
sults from the GELA study [83], indicating OS and
PFS of 49% and 39% at 8 years in chemotherapy-
treated patients, respectively. In the Spanish study of
19 transplanted patients with angioimmunoblastic T
cell lymphoma (AITL) (15 front-line, 4 salvage) [84],
3-year OS and PFS were 60% and 55%, respectively.
In the NLG trial [85], including 30 patients treated
with intensive chemotherapy followed by ASCT, the
corresponding figures were 50% and 47% at 4 years,
respectively. The largest study of transplanted AITL
patients is based on the EBMT registry [86]. That ret-
rospective study of 146 patients showed an NRM of
5% at 12 months and OS of 59% at 4 years. The out-
come was better in patients transplanted in first com-
plete remission with PFS of 56% at 4 years.
Historically, EATCL has had a very poor outcome,
and early results of ASCT were not promising either
[87]. However, in the prospective trial of the NLG,
the outcome of 21 patients with EATL showed some
promise. With a median follow-up of 45 months, OS
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The recently published study from the United
Kindgom [89] reported 26 patients with EACTL
who received CHOP followed by three IEV courses
(ifosfamide etoposide epirubicin) courses alternating
with intermediate-dose methotrexate followed by
high-dose therapy; actually, 14 patients received
ASCT. OS and PFS were a promising 60% and 52%
at 5 years and superior when compared with the his-
toric controls treated with anthracycline-based che-
motherapy (OS 22% at 5 years).
At present, no prospective phase III studies regard-
ing ASCT following first-line therapy are available,
but current indirect evidence suggests the potential
utility of ASCT in this setting. Taking into account
the generally poor outcome of the most histologic sub-
types of PTCL and the currently available phase II
data, ASCT can be considered a clinical option in pa-
tients with systemic PTCL, excluding alk-positive
ALCL if these patients respond to induction therapy
and are otherwise eligible for high-dose therapy. Opti-
mally, these patients should be treated within prospec-
tive clinical trials. As about 30% to 40% of PTCL
patients scheduled to ASCT do not receive it mostly
because of poor response to chemotherapy or early
progression, improvements in induction treatment
are clearly needed. A currently ongoing phase III
ACT-1 trial is evaluating in a randomized fashion
the addition of alemtuzumab to CHOP-14 induction
therapy; ASCT consolidation is used in both arms.
Allogeneic transplantation
As no randomized studies are available, experiences
with alloSCT are based on small single-center series or
registry series. With the exception of leukemic forms
of PTCLs [90], most studies have included only re-
lapsed patients. The Italian study [91] suggested
a low NRM (6% at 2 years) among 17 patients receiv-
ing RIC alloSCT. The conditioning consisted of thio-
tepa, fludarabine, and cyclophospamide, and the donor
was an HLA-identical sibling in all but 2 patients. OS
and PFS at 3 years were 81% and 64%, respectively. In
the French registry series including 77 patients with
histologically aggressive T cell lymphomas treated
with myeloablative conditioning in 57 patients,
NRM was 33% at 5 years [92]. OS and EFS were
57% and 53% at 5 years, respectively. In the EBMT se-
ries including 45 patients with AITL, NRM was 25%
at 1 year. PFS and OS at 3 years were 53% and 64%,
respectively [93]. The recent retrospective analysis
from Japan including almost 400 patients with adult
T cell leukemia [94] reported an NRM ranging be-
tween 37% and 52% at 3 years depending on stem
cell source; the highest NRM was observed in patients
receiving cord blood grafts. OS was 33% at 3 years in
this large retrospective analysis. AlloSCT showed
some efficacy in selected patients, with advanced-stage high-risk patients with mycosis fungoides/Sezary
symdrome with an estimated OS of 54% at 3 years in
the recent analysis based on the EBMT registry [95].
Thirty-six patients had mycosis fungoides and 24 had
Sezary syndrome. In this study, 44 patients received
an RIC conditioning and 25 underwent T cell deple-
tion. Patients with unrelated donors had poorer out-
comes, and T cell depletion was associated with
a higher risk of relapse.
Currently, an Italian trial is comparing ASCT and
alloSCT after first-line induction therapy in PTCL.
Also, a trial started in Germany is comparing first-
line ASCT with alloSCT in this patient group.
AlloSCT is currently an option in patients who relapse
after ASCT but are chemosensitive. It also deserves
consideration in patients who relapse after nontrans-
plantation first-line therapy, as results of ASCT are
usually poor in this setting.HL
Newly diagnosed patients with HL have an excel-
lent prognosis, as the vast majority of them can be
cured with initial therapy. In contrast, the prognosis
of patients relapsing after first-line therapy with either
combination chemotherapy (CT) or CT followed by
radiotherapy (RT) remains poor in many cases. In
most of these patients, ASCT is today considered to
be the treatment of choice.
Autologous transplantation
The use of ASCT is now considered the standard
of care for relapsed HL patients [9]. Two randomized
trials showed significant benefit in freedom from treat-
ment failure (FFTF) for ASCT over conventional CT
for relapsed disease [96,97]. The results of these trials
have resulted in the recommendation of ASCT at time
of first relapse for even the most favorable patients,
although salvage RT can offer an effective treatment
for selected subsets of patients with relapsed or
refractory HL. The lack of a survival benefit in these
randomized trials has been attributed to patients in
the nontransplantation arm undergoing transplan-
tation at the time of the second relapse.
The first randomized trial of transplantation for
relapsed disease compared ASCTwith BEAM as a pre-
parative regimen to mini-BEAM without autologous
transplantation [96] in patients with active HL, for
whom conventional therapy had failed. Twenty
patients were assigned treatment with BEAM plus
ASCT and 20 with mini-BEAM. Five BEAM recipi-
ents died compared with 9 mini-BEAM recipients.
Both 3-year EFS and PFS showed significant differ-
ences in favor of BEAM plus ASCT (P 5 .025 and
P 5 .005, respectively). There were no differences in
OS. In the second randomized trial performed by
investigators of the German Hodgkin’s Disease Study
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2 cycles of Dexa-BEAM and either 2 further courses of
Dexa-BEAM or high-dose BEAM [97]. Only patients
with chemosensitive disease after 2 courses of Dexa-
BEAM proceeded to further treatment. There was
a significant improvement in 3-year FFTF for patients
undergoing ASCT compared with 4 cycles of Dexa-
BEAM (55% versus 34%, P 5 .019). Three-year
FFTF was significantly better for patients treated
with BEAM, regardless of whether the first relapse
had occurred early (\12 months) (41% versus 12%,
P 5 .007) or late (.12 months) (75% versus 44%,
P 5 .02). There was no statistically significant differ-
ence in OS for any subgroup of patients.
In order to improve the results of ASCT, the
GHSG has employed a sequential high-dose chemo-
therapy (CT) before the intensive procedure [98].
Treatment started with 2 cycles of DHAP to reduce
tumor burden. Patients achieving a CR or PR subse-
quently received a high-dose CT program with cyclo-
phosphamide (4 g/m2 i.v.), methotrexate (8 g/m2 i.v.),
vincristine (1.4 mg/m2 i.v.), and etoposide (2 g/m2 i.v.).
Patients were then autografted using BEAM.Response
rate after the final evaluation was 80%. FFTF and OS
for patients with early relapse were 62% and 78%, re-
spectively, and for patients with late relapse, 63% and
79%, respectively. These promising results prompted
the GHSG to develop a prospective phase III clinical
trial looking at relapsed patients withHL being treated
either with the conventional salvage approach (DHAP
 2 cycles plus ASCT versus DHAP plus high-
dose sequential protocol plus ASCT). Somewhat unex-
pectedly, there were no significant differences in terms
of PFS, FFTF, or OS between the study arms [99].
Prognosis of patients with primary refractory dis-
ease is extremely poor. Nevertheless, and as opposed
to NHL, where chemorefractory patients are not sal-
vaged by a transplant, there seems to be a general con-
sensus that even patients who fail first- and second-line
CT may still enjoy a 20% to 30% chance of cure with
ASCT.
The impact of ASCT in the long-term outcome of
patients with relapsed/refractory HL is not the same
in all subgroups of patients. Several authors have retro-
spectively analyzed prognostic factors at first relapse. In
this sense, time to relapse (\12 months versus
$12 months) [100-102], extranodal disease at relapse
[100,102], advanced stage and anemia at relapse [101],
B symptoms [102,103], and refractory disease [103]
were found to be important. More recently, the role
of positron emission tomography has also been
analyzed in theASCTsetting. In a groupof 101 patients
with both NHL and HL, both fluorodeoxyglucose-
positron emission tomography after 2 cycles of chemo-
therapy and clinical risk score were independent
prognostic factors for failure-free survival after ASCT
[104]. In a similar way, the group from the M.D.AndersonCancerCenter indicated that pretransplanta-
tion positive PET/Gallium scans were able to predict
poor outcome after ASCT in patients with relapsed/re-
fractory HL [105].
In order to improve the results of ASCT, both new
monoclonal antibodies (brentuximab vedotin, SGN-
35) and histone deacetylase inhibitors (panobinostat,
OLDH568) are being tested in prospective clinical
trials as maintenance therapy in order to prevent
relapse in those patients with high-risk relapsed HL
being treated with an ASCT.
Allogeneic transplantation
Two larger registry-based studies published in
1996 gave disappointing results regarding the role of
myeloablative alloSCT in patients with relapsed HL.
One hundred HL patients allografted from HLA-
identical siblings were reported by the International
Bone Marrow Transplant Registry [106]. The 3-year
rates for OS, disease-free survival, and the probability
of relapse were 21%, 15%, and 65%, respectively.
The major problems after transplantation were persis-
tent or recurrent disease or respiratory complications,
which accounted for 35% to 51% of deaths. A
case-matched analysis including 45 allografts and 45
autografts reported to the EBMT [107] did not find
significant differences in actuarial probabilities of OS,
PFS, and relapse rates between allo-SCT and ASCT
(25%, 15%, 61%versus 37%, 24%, 61%, respectively).
The actuarial NRM at 4 years was significantly higher
for allografts than for autografts (48% versus 27%).
The advent of RIC protocols prompted the EBMT
to compare the outcomes after RIC or myeloablative
conditioning in patients with HL [108]. NRMwas sig-
nificantly decreased in the RIC allo-SCT group (23%
versus 46% at 1 year) (hazard ratio [HR] 5 2.43; 95%
confidence interval [CI], 1.48-3.98; P\ .001). PFS and
OS were also better in the reduced-intensity group
(HR 5 1.28; 95% CI, 0.92-1.78; P 5 .10; and HR 5
1.62, 95% CI 1.15-2.28; P 5 .005, respectively). The
development of cGVHD significantly decreased the
incidence of relapse after transplantation, which trans-
lated into a better PFS and OS. This analysis indicated
that RIC allo-SCT was able to reduce NRM and
improve the long-term outcome of these patients.
The largest cohort of patients treated with RIC
allo-SCT in HL includes 285 patients [109] with
heavily pretreated disease. At the time of allo-SCT,
47 patients (17%) were in CR, 123 patients (43%)
had chemosensitive disease, and 115 patients (40%)
had chemoresistant disease or untested relapse. The
100-day NRM was 12% but increased to 20% at
12 months, and to 22% at 3 years; it was significantly
higher for patients with chemoresistant disease. Two-
year PFS was 29% and again significantly worse for
patients with chemoresistant disease (P\ .001). The
development of cGVHD was associated with a higher
Table 1. Potential Ways to Improve Efficacy and Safety of
Stem Cell Transplants in Lymphoma Patients
ASCT - safety
- use of comorbidity indexes
- better prevention of severe mucositis (palifermin, supersaturated
calcium phosphate oral rinse)
- antimicrobial prophylaxis during neutropenia
- optimized supportive care during neutropenic sepsis
- efficacy
- plerixafor to increase the number of patients with successful stem cell
collection
- more effective therapy before ASCT (eg, alemtuzumab in PTCL, new
drugs)
- radioimmunotherapy with high-dose therapy (eg, Z-BEAM)
(eg, FL, MCL)
- maintenance therapy with antibodies, for example, rituximab after
ASCT (eg, FL, MCL)
- bortezimib after ASCT (MCL)
- pcr monitoring after ASCT and preemptive treatment with, for
example, antibodies
AlloSCT - safety
- risk score, comorbidity indexes
- RIC regimens, reduced toxicity regimens
- more efficient GVH prophylaxis
- viral monitoring and preemptive treatment (eg, CMV)
- fungal monitoring and prophylaxis (eg, posaconazole in patients
with GVHD)
- efficacy
- better selection of donors to maximize GVL effects
- combination to antibodies or radioimmunotherapy in conditioning
regimens
- maintenance therapy with antibodies
- molecular monitoring posttransplantation and treatment of early
relapse/preemptive treatment (antibodies, DLI)
Z indicates ibritumomab tiuxetan; BEAM, carmustine, etoposide, cytar-
abine, melphalan.
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analysis, the development of either acute (aGVHD) or
cGVHD by 9 months posttransplantation was associ-
ated with a significantly lower relapse rate.
Several small phase II prospective clinical trials or
multicenter retrospective studies have been published.
The M.D. Anderson Cancer Center updated experi-
ence [110] indicates a projected 2-year OS and PFS of
64% and 32%, with a 2-year projected risk of disease
progression of 55%.Therewas a trend for the response
status before alloSCT to favorably impact PFS (P 5
.07) and disease progression (P 5 .049), but not OS.
Partial responders and patients with stable refractory
disease fared similarly with regard to OS and PFS. In
the Spanish experience with 40 patients treated with
the combination of fludarabine (150 mg/m2) and mel-
phalan (140 mg/m2), the response rate 3 months after
RIC allo-SCTwas 67% [111]. Eleven patients received
DLIs for relapse or persistent disease, and 6 patients
(54%) responded. OS and PFS were 48% and 32% at
2 years, respectively. Refractoriness to chemotherapy
was the only adverse prognostic factor for both OS
and PFS. Peggs et al. [112] explored the effects of
in vivo T cell depletion with alemtuzumab followed
by fludarabine (150 mg/m2) and melphalan (140 mg/
m2) in multiply relapsed patients. All patients en-
grafted, grade II-IV aGVHD occurred in 16% of
patients, and 14% developed cGVHD before DLIs.Nineteen patients received DLIs for progression (n 5
16) or mixed chimerism (n 5 3). Nine patients (56%)
showed a response, which was significantly associated
with aGVHD and/or extensive cGVHD. NRM was
16% at 730 days. Projected 4-year OS and PFS were
56% and 39%, respectively.
Finally, the results of the largest prospective phase
II clinical trial (Sureda et al., unpublished), including
78 patients with a median follow-up of 4 years after
alloSCT, indicate an NRM of 8% at 100 days and
15% at 1 year. Relapse was the major cause of failure.
PFS was 48% at 1 year and 24% at 4 years. Chronic
GVHD was associated with a lower relapse incidence
and a better PFS. Patients allografted in CR had a sig-
nificantly better outcome. In this study, OSwas 71% at
1 year and 43% at 4 years, respectively.
Relapse is the major cause of failure for those pa-
tients with relapsed/refractory HL being considered
candidates for such an approach. Only patients in
CR or very good PR should be considered adequate
candidates for an allo-SCT, at least with the current
protocols. In this sense, new salvage strategies to try
to put patients into a better response should be sought.
Also, the role of PET should be further explored in this
setting. Modulation of the intensity of the condition-
ing regimen can also result in a lower relapse rate after
allo SCT. Low-dose TBI containing regimens seem to
be associated with a high relapse rate in the RIC allo
setting [109]. Finally, the so-called maintenance strat-
egy currently being explored in the ASCT setting with
new drugs such as brentuximab vedotin can also be
analyzed in the alloSCT setting.FUTURE PERSPECTIVES
Alongwith developments in lymphoma therapy like
new antibodies and new molecules currently in trials,
the role of stem cell transplant approaches is also likely
to evolve in the near future. RIC allotransplants have
generally been associated with amore favorable toxicity
profile than myeloablative conditioning, although
much has to be learned about optimizing the condition-
ing based on patient and disease characteristics. RIC
[113] has rapidly, to a large extent, replaced myeloabla-
tive conditioning, especially in heavily pretreated
lymphomapatients.Various biologic prognostic factors
may becomemore important in defining indications for
stem cell transplants, at least as a part of first-line ther-
apy. Novel mobilization strategies, including use of
plerixafor for stem cell mobilization in patients with
failed mobilization [114] or preemptively [115,116],
may increase the number of patients proceeding to
ASCT. In the allogeneic setting, in addition to the
donor availability also risk score of a patient [51], may
be important in clinical decision making. As in all clin-
icalmedicine, judgment of other treatmentoptionswith
their potential risks and benefits is important because
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and clinical features andoutcomesmay be very different
among the same lymphoma types.
There is clearly room for improvements in our
current transplant approaches in order to improve
efficacy and decrease toxicity associated with the pro-
cedure (Table 1). Inclusion of radioimmunoconjugates
to conditioning regimens in autologous [39] and allo-
geneic settings [48,49] may be useful in order to
improve outcomes. Prophylactic or preemptive DLIs
may be beneficial, especially in patients receiving
T cell–depleted grafts [112]. Targeted or preemptive
therapy with rituximab, bortezomib, or novel mono-
clonal agents like brentuximab vedotin for CD30-
positive lymphomas (ALCL, HL) [117] may be useful
to improve outcomes, but more data are needed.
It is to be expected that the number of ASCTs may
decrease somewhat in the near future. As results of
alloSCT are slowly but continuously improving
[118,119], it is likely that alloSCT will replace ASCT
in some clinical settings, at least in patients with low
risk scores for NRM and high-risk disease features.
Continuous efforts are needed to improve current
risk-benefit ratios of alloSCT. As risk of relapse is still
substantial, for example in patients with DLBCL or
HL after alloSCT, ways to improve pretransplantation
therapy and conditioning regimens with improving ef-
ficacy but without increasing toxicity and perhaps also
manipulating graft characteristics should be studied
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